StreetInsider.com News Articles

Sensorion sets 50-to-1 reverse share split effective September 15

Wed, 29 Jul 2026 01:30:15 -0400

Sensorion (Euronext Growth Paris: ALSEN), a clinical-stage biotechnology company focused on hearing loss treatments, announced the implementation of a reverse share split that will consolidate 50 existing shares into one new share.

The exchange will convert 515,648,600 existing shares with a par value of €0.10 each into 10,312,972 new shares with a par value of €5 each. According to the company, the transaction is a technical exchange and will not affect the total value of shares held by each shareholder or the company's overall share capital.

The reverse share split notice was published July 29, 2026, in the Bulletin des Annonces Légales

Sensorion sets 50-to-1 reverse share split effective September 15

Wed, 29 Jul 2026 01:30:15 -0400

The reverse share split notice was published July 29, 2026, in the Bulletin des Annonces Légales

Sensorion sets 50-to-1 reverse share split effective September 15

Wed, 29 Jul 2026 01:30:15 -0400

The reverse share split notice was published July 29, 2026, in the Bulletin des Annonces Légales

Sensorion sets 50-to-1 reverse share split effective September 15

Wed, 29 Jul 2026 01:30:15 -0400

The reverse share split notice was published July 29, 2026, in the Bulletin des Annonces Légales

Sensorion Announces a Reverse Share Split of its Shares

Wed, 29 Jul 2026 01:30:00 -0400

Reverse share split by the exchange of 50 existing shares with a par value of €0.10 for 1 new share with a par value of €5
Publication of the reverse share split notice: July 29, 2026
Start of the reverse share split: August 13, 2026
Effective date of the reverse share split (listing of new shares): September 15, 2026

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces the implementation of the reverse share split of

Sensorion Announces a Reverse Share Split of its Shares

Wed, 29 Jul 2026 01:30:00 -0400

Reverse share split by the exchange of 50 existing shares with a par value of €0.10 for 1 new share with a par value of €5
Publication of the reverse share split notice: July 29, 2026
Start of the reverse share split: August 13, 2026
Effective date of the reverse share split (listing of new shares): September 15, 2026

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion Announces a Reverse Share Split of its Shares

Wed, 29 Jul 2026 01:30:00 -0400

Reverse share split by the exchange of 50 existing shares with a par value of €0.10 for 1 new share with a par value of €5
Publication of the reverse share split notice: July 29, 2026
Start of the reverse share split: August 13, 2026
Effective date of the reverse share split (listing of new shares): September 15, 2026

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion Announces a Reverse Share Split of its Shares

Wed, 29 Jul 2026 01:30:00 -0400

Reverse share split by the exchange of 50 existing shares with a par value of €0.10 for 1 new share with a par value of €5
Publication of the reverse share split notice: July 29, 2026
Start of the reverse share split: August 13, 2026
Effective date of the reverse share split (listing of new shares): September 15, 2026

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion Announces a Reverse Share Split of its Shares

Wed, 29 Jul 2026 01:30:00 -0400

Reverse share split by the exchange of 50 existing shares with a par value of €0.10 for 1 new share with a par value of €5
Publication of the reverse share split notice: July 29, 2026
Start of the reverse share split: August 13, 2026
Effective date of the reverse share split (listing of new shares): September 15, 2026

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion Announces a Reverse Share Split of its Shares

Wed, 29 Jul 2026 01:30:00 -0400

Reverse share split by the exchange of 50 existing shares with a par value of €0.10 for 1 new share with a par value of €5
Publication of the reverse share split notice: July 29, 2026
Start of the reverse share split: August 13, 2026
Effective date of the reverse share split (listing of new shares): September 15, 2026

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion Announces a Reverse Share Split of its Shares

Wed, 29 Jul 2026 01:30:00 -0400

Reverse share split by the exchange of 50 existing shares with a par value of €0.10 for 1 new share with a par value of €5
Publication of the reverse share split notice: July 29, 2026
Start of the reverse share split: August 13, 2026
Effective date of the reverse share split (listing of new shares): September 15, 2026

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion Announces a Reverse Share Split of its Shares

Wed, 29 Jul 2026 01:30:00 -0400

Reverse share split by the exchange of 50 existing shares with a par value of €0.10 for 1 new share with a par value of €5
Publication of the reverse share split notice: July 29, 2026
Start of the reverse share split: August 13, 2026
Effective date of the reverse share split (listing of new shares): September 15, 2026

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Wed, 10 Jun 2026 01:30:00 -0400

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to

Sensorion Appoints Fred Chereau as Chief Executive Officer

Mon, 18 May 2026 01:30:00 -0400

Fred Chereau brings extensive leadership experience across the biotechnology and pharmaceutical industries, with deep expertise in gene therapy and company building, driven by a lifelong commitment to patients with rare diseases.
Fred joins from Alexion – AstraZeneca Rare Disease, where he served as Senior Vice President, Strategy and Business Development, following his tenure as President and CEO of LogicBio Therapeutics, which was acquired by Alexion in 2022.
Amit Munshi will continue as Chairman of the Board of Directors, having served as Interim Chief Executive Officer since February 2026.

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN)